Depression Symptoms Treatment
Archive for the ‘Paxil (Paroxetine)’ Category
Drug Approvals
(British Approved Name, US Adopted Name, rINN)
INNs in other languages (French, Latin, and Spanish):
Synonyms: BRL-29060; FG-7051; Paroksetiini; Paroxetin; Paroxetinum
BAN: Paroxetine
USAN: Paroxetine
INN: Paroxetine [rINN (en)]
INN: Paroxetina [rINN (es)]
INN: Paroxétine [rINN (fr)]
INN: Paroxetinum [rINN (la)]
INN: Пароксетин [rINN (ru)]
Chemical name: (-)-trans-5-(4-p-Fluorophenyl-3-piperidylmethoxy)-1,3-benzodioxole
Molecular formula: C19H20FNO3 =329.4
CAS: 61869-08-7
ATC code: N06AB05
Paroxetine Hydrochloride
Drug Approvals
(British Approved Name Modified, rINNM)
International Nonproprietary Names (INNs) in main languages (French, Latin, and Spanish):
Synonyms: BRL-29060A; Paroksetiinihydrokloridihemihydraatti; Paroksetino hidrochloridas hemihidratas; Paroxetin hydrochlorid; Paroxetina, hidrocloruro de; Paroxetine Hydrochloride Hemihydrate; Paroxetinhydrokloridhemihydrat; Paroxetini Hydrochloridum; Paroxetini Hydrochloridum Hemihydricum
BAN: Paroxetine Hydrochloride [BANM]
INN: Paroxetine Hydrochloride [rINNM (en)]
INN: Hidrocloruro de paroxetina [rINNM (es)]
INN: Read more [...]
January 25th, 2010 by admin
Paxil (Paroxetine) for the treatment of social anxiety disorder & social phobia
A recent study adds to the body of evidence suggesting that the drug Paxil (paroxetine HCl) is effective in treating social anxiety disorder / social phobia.
* note: social anxiety disorder is characterized by the fear of being observed or evaluated by others; sufferers report an overwhelming fear of embarrassment in social and performance situations.
* researchers at the University of Southampton conducted a 12-week, multi-centre, double-blind, placebo-controlled clinical trial to compare the efficacy of Paxil (20-50 mg daily) to placebo, in 290 patients with social anxiety disorder.
* found a statistically significant symptom improvement in patients treated with Paxil within as little as four weeks of treatment onset, as measured by the Liebowitz Social Anxiety Scale (LSAS), which provides an assessment of a patient's level of fear and avoidance of performance and/or social situations.
* the researchers say that Paxil was associated with a definitive reduction in symptoms of social anxiety disorder, increased participation in social activity, as well as a significant improvement in overall well Read more [...]
Anti-depressant Paxil joins the list
The anti-anxiety drug Paxil (paroxetine HCl) has joined Zoloft as an FDA-approved treatment for post traumatic stress disorder (PTSD), according to its maker, GlaxoSmithKline. Zoloft (sertraline hydrochloride) was the first anti-depression drug approved by the FDA to treat PTSD in late 1999.
Post traumatic stress disorder affects millions of people, usually after they have either seen or been part of an intensely emotional or dramatic event. This can run the gamut from being in combat to witnessing an accident.
Paxil's approval came after clinical trials that showed "paroxetine was effective for both men and women," according to research published in the issue of the American Journal of Psychiatry.
Here's the article's conclusion: "Doses of 20 and 40 mg/day of paroxetine are effective and well tolerated in the treatment of adults with chronic post traumatic stress disorder."
Post traumatic stress disorder first came to the public's attention as a diagnosable and treatable condition during the Vietnam War years. Many veterans began exhibiting such symptoms Read more [...]
Study sees treatment option for women who breast-feed.
Breast-fed infants of mothers taking the selective serotonin reuptake inhibitor (SSRI) antidepressant paroxetine HCl (Paxil / SmithKline Beecham) had very low traces of the medication in their blood, according to a study at Emory University School of Medicine’s Pregnancy and Postpartum Mood Disorders Program. The study on infant exposure during breast-feeding indicates that postpartum depression, which is a common condition, can be treated with the selective serotonin reuptake inhibitor (SSRI).
The Food and Drug Administration has approved the marketing of the selective serotonin reuptake inhibitor paroxetine hydrochloride (Paxil / SmithKline Beecham) for the treatment of depression. It is the third of a new group of antidepressants that are supplanting older drugs. The other two are fluoxetine (Prozac/Lilly) and sertraline (Zoloft/Pfizer). Paroxetine hydrochloride has a chemical structure unrelated to other selective serotonin uptake inhibitors.
Controlled trials with outpatients have demonstrated the efficacy of paroxetine (Paxil) for DSM-III major depressive disorders. The benefits of therapy become apparent within about two weeks. (Claghorn J. Int Clin Psychopharmacol 1992; 6(Suppl 4): 25-30.) Paroxetine (Paxil) has the particular advantage of improving sleep without interfering with psychomotor function and is relatively safe in overdose situations. (Montgomery SA. Int Clin Psychopharmacol 1992; 6 (Suppl 4): 91-100.) Patients' cognitive functions have been found to improve from the start of therapy. (Hindmarch I. Int Clin Psychopharmacol 1992; 6(Suppl 4): 65-67.) Paroxetine's antidepressive Read more [...]